Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | CETP | P11597 | 2/20 | 0.45 |
| ▸ | PDE2A | O00408 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565147 | 0.85 | CTSS (0.47) | SLC6A4SLC6A2HTR2AKCNH2PDE2A | |
| SCHEMBL5235367 | 0.84 | ALDH1A1 (0.43) | SLC6A4SLC6A2HTR2AKCNH2PDE2A | |
| SCHEMBL2669965 | 0.84 | DAO (0.51) | SLC6A4HTR2AKCNH2PDE2AMRGPRX4 | |
| SCHEMBL10656350 | 0.83 | SLC6A4 (0.48) | SLC6A4SLC6A2HTR2AKCNH2PDE2A | |
| Ethylamine SCHEMBL4235858 | 0.83 | SLC6A4 (0.43) | SLC6A4SLC6A2HTR2AKCNH2PDE2A | |
| SCHEMBL4240974 | 0.82 | SLC6A4 (0.48) | SLC6A4SLC6A2HTR2AKCNH2CETP | |
| SCHEMBL3105504 | 0.82 | GABRA2 (0.43) | SLC6A4SLC6A2HTR2AKCNH2PDE2A | |
| SCHEMBL11542294 | 0.82 | ESR1 (0.46) | ESR1ESR2ALDH1A1HSP90AA1CYP2D6 | |
| SCHEMBL5436712 | 0.82 | SLC6A4 (0.43) | SLC6A4SLC6A2HTR2AKCNH2PDE2A | |
| SCHEMBL15133743 | 0.81 | ESR1 (0.44) | SLC6A4HTR2AKCNH2PDE2AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019516-A1 | ASYMMETRIC PHASE TRANSFER CATALYSIS | Merck Sharp & Dohme Corp. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3704118-B1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| EP-2825536-B1 | BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS | MERCK SHARP & DOHME (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10314820-B2 | Imidazole-based heterocyclic compounds | PROCOMCURE BIOTECH GMBH (AT) | 2019-06-11 | — | — | US | disclosed |
| EP-3008045-B1 | ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS | ANTABIO SAS (FR) | 2018-05-09 | — | — | EP | disclosed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | disclosed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | disclosed |
| US-20170340613-A1 | Novel Imidazole-Based Heterocyclic Compounds | PROCOMCURE BIOTECH GMBH (AT) | 2017-11-30 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | NEUROGEN CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | SLC6A4 773/4885SLC6A2 364/4885HTR2A 1679/4885 |
| US-20080275052-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP2K2, MAP2K6, MAP2K1 | SLC6A4 3901/4885SLC6A2 3438/4885HTR2A 2622/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | SLC6A4 4659/4885SLC6A2 4437/4885HTR2A 3766/4885 |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | DRD3, DRD2, DRD4 | SLC6A4 70/4885SLC6A2 41/4885HTR2A 51/4885 |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | C5AR1, C5AR2, C3AR1 | SLC6A4 1960/4885SLC6A2 3885/4885HTR2A 464/4885 |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | SLC6A4 4444/4885SLC6A2 4494/4885HTR2A 4134/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | SLC6A4 773/4885SLC6A2 364/4885HTR2A 1679/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | SLC6A4 773/4885SLC6A2 364/4885HTR2A 1679/4885 |
| US-20170340613-A1 | Novel Imidazole-Based Heterocyclic Compounds | SLC11A2, MIF, NISCH | SLC6A4 4730/4885SLC6A2 4463/4885HTR2A 4616/4885 |
| US-10314820-B2 | Imidazole-based heterocyclic compounds | MIF, SLC11A2, TLR5 | SLC6A4 4665/4885SLC6A2 4273/4885HTR2A 4590/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | SLC6A4 4527/4885SLC6A2 4867/4885HTR2A 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.